Pharmacokinetic approaches to treatment of drug addiction

Expert Review of Clinical Pharmacology

Volumn 1, Issue 2, 2008, Pages 277-290

  Gorelick, David A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Bacterial esterase; Butyrylcholinesterase; Cocaine; Drug addiction; Methamphetamine; Monoclonal antibody; Nicotine; Pharmacokinetics; Phencyclidine; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; AME 359; BENZOYLECGONINE; BUPRENORPHINE; CHOLINESTERASE; COCAINE VACCINE; CYT 002; ESTERASE; GNC 92H2; HEROIN VACCINE; INTERVEXIN METH; INTERVEXIN PCP; LIDOCAINE; METHADONE; METHAMPHETAMINE VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 15A10; MONOCLONAL ANTIBODY 2E2; MONOCLONAL ANTIBODY 6H4; MORPHINE VACCINE; NALTREXONE; NIC 311; NICOTINE; NICOTINE VACCINE; NICQB; PLACEBO; RHINOVAX; RIBOFLAVIN; TA CD; TA NIC; VACCINE;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; BINDING AFFINITY; CLINICAL TRIAL; COCAINE DEPENDENCE; CONVULSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BINDING; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEROIN DEPENDENCE; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE TENDERNESS; MALAISE; METHADONE TREATMENT; MORPHINE ADDICTION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OPIATE ADDICTION; PASSIVE IMMUNIZATION; PHARMACODYNAMICS; PSYCHOSOCIAL CARE; RECEPTOR BLOCKING; REVIEW; SINGLE DRUG DOSE; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 49249135911     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.2.277     Document Type: Review

References (74)

1. Epstein DH, Preston KL, Stewart J, Shaham Y. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Pychopharmacology (Berl.) 189, 1-16 (2006).
2. Nelson RA, Boyd SJ, Ziegelstein RC et al. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend. 82, 19-24 (2006).
3. Harwood HJ, Myers TG. New Treatments For Addiction: Behavioral, Ethical, Legal, and Social Questions. Harwood HJ, Myers TG (Eds). National Academies Press, Washington, DC, USA (2004).
4. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR. The future of vaccines in the management of addictive disorders. Curr. Psychiatry Rep. 9, 381-387 (2007).
5. Keyler DE, Roiko SA, Benlhabib E et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab. Dispos. 33, 1056-1061 (2005).
6. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob. Res. 9, 511-518 (2007).
7. Ray R, Schnoll RA, Lerman C. Pharmacogenetics and smoking cessation with nicotine replacement therapy. CN3 Drugs 21, 525-533 (2007).
8. Kosten TR, Rosen M, Bond J et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20, 1196-1204 (2002).
9. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry 58, 158-164 (2005).
10. Martell BA, Mitchell E, Poling J, Gardner T, Kosten TR. Efficacy of a cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 21 June, 2007.
11. Gardner T, Martell BA, Poling J, Mitchell E, Kosten T. Gender differences in a cocaine vaccine trial of TA-CD/08. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 18 June, 2007.
12. Haney M, Gunderson EW, Collins ED, Foltin RW. Cocaine vaccine: smoked cocaine administration in humans. Presented at: College on Problems of Drug Dependence Annual Meeting. Scottsdale, AZ, USA, 19 June, 2006.
13. Martinez D, Haney M, Foltin R et al. The use of PET to assess a vaccine for cocaine dependence. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 20 June, 2007.
14. Heading CE. Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr. Opin. Investig. Drugs 8, 71-77 (2007).
15. Maurer, P, Jennings GT, Willers J et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35, 2031-2040 (2005).
16. Maurer P, Bachmann MF. Therapeutic vaccines for nicotine dependence. Curr. Opin. Mol. Ther. 8, 11-16 (2006).
17. Hatsukami DK, Rennard S, Jorenby D et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 78, 456-467 (2005).
18. Rennard S. A randomized placebo-controlled trial of a conjugate nicotine vaccine (NicVAX) in smokers who want to quit: 12-month results. Presented at: American Heart Association Scientific Sessions. Orlando, FL, USA, 11 July, 2007.
19. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 22, 809-819 (2000).
20. Keyler DE, Shoeman D, LeSage MG, Calvin AD, Pentel PR. Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J. Pharmacol. Exp. Ther. 305, 587-592 (2003).
21. McNeil C. Nicotine vaccines move toward pivotal trials. J. Natl Cancer Inst. 98, 301 (2006).
22. Oliver JL, Pashmi G, Barnett P et al. Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies. Vaccine 25, 7354-7362(2007).
23. Orson F, Haile CN, Kinsey B et al. Methamphetamine vaccine in rodents. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 21 June, 2007.
24. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+) methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int. Immunopharmacol. 1, 329-338 (2001).
25. Anton B, Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24, 3232-3240 (2006).
26. Hrafnkelsdottir K, Valgeirsson J, Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol. Pharm. Bull. 28, 1038-1042 (2005).
27. Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J. 8, E383-E390(2006).
28. Peterson EC, Gunnell M, Che Y et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther. 322, 30-39 (2007).
29. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl Acad. Sci. USA 97, 6202-6206 (2000).
30. Norman AB, Norman MK, Buesing WR, Taber MR, Tsibulsky VL, Ball WJ. A chimeric human anti-cocaine monoclonal antibody antagonizes the cocaine-induced priming of self- administration in rats. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 20 June, 2007.
31. Carrera MR, Trigo JM, Wirsching P, Roberts AJ, Janda KD. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol. Biochem. Behav. 81, 709-714 (2005).
32. Norman AB, Ball WJ. Humanized anti-cocaine monoclonal antibody as a potential immunotherapy for cocaine abuse. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 20 June, 2007.
33. Norman AB, Taber MR, Norman MK, Buesing WN, Pesce AJ, Ball WJ. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J. Pharmacol. Exp. Ther. 320, 145-153 (2007).
34. Byrnes-Blake KA, Laurenzana EM, Carroll FI et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur. J. Pharmacol. 461, 119-128 (2003).
35. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur. J. Pharmacol. 521, 86-94 (2005).
36. Laurenzana EM, Byrnes-Blake KA, Milesi-Halle A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab. Dispos. 31, 1320-1326 (2003).
37. Gentry WB, Laurenzana EM, Williams DK et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int. Immunopharmacol. 6, 968-977 (2006).
38. McMillan DE, Hardwick WC, Li M et al. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther. 309, 1248-1255 (2004).
39. Daniels JR, Wessinger WD, Hardwick WC et al. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology (Berl.) 185, 36-44 (2006).
40. Laurenzana EM, Gunnell MG, Gentry WB, Owens SM. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J. Pharmacol. Exp. Ther. 306, 1092-1098 (2003).
41. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab. Dispos. 34, 906-912 (2006).
42. Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J. Pharmacol. Exp. Ther. 292, 831-837 (2000).
43. Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, Owens SM. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J. Pharmacol. Exp. Ther. 302, 119-126 (2002).
44. Pentel PR, Dufek MB, Roiko SA, LeSage MG, Keyler DE. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. J. Pharmacol. Exp. Ther. 317, 660-666 (2006).
45. Owens M. Making effective and safe antibody medications for treating phencyclidine and methamphetamine addiction. Presented at: Coke on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 20 June, 2007.
46. Carrera MR, Kaufmann GF, Mee JM, Meijler MM, Koob GF, Janda KD. Treating cocaine addiction with viruses. Proc. Natl Acad Sci. USA 101, 10416-10421 (2004).
47. Xu Y, Hixon MS, Yamamoto N et al. Antibody-catalyzed anaerobic destruction of methamphetamine. Proc. Natl Acad. Sci. USA 104, 3681-3686 (2007).
48. Dickerson TJ, Yamamoto N, Janda KD. Antibody-catalyzed oxidative degradation of nicotine using riboflavin. Bioorg. Med. Chem. 12, 4981-4987 (2004).
49. Turner JM, Larsen NA, Basran A et al. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41, 12297-12307 (2002).
50. Potter PM, Wadkins RM. Carboxylesterases - deroxifying enzymes and targets for drug therapy. Curr. Med. Chem. 13, 1045-1054 (2006).
51. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 48, 159-165 (1997).
52. Carmona GN, Schindler CW, Greig NH et al. Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. Eur. J. Pharmacol. 517, 186-190 (2005).
53. Dalby PA. Engineering enzymes for biocatalysis. Recent Patents on Biotechnology 1, 1-9 (2007).
54. Sun H, Shen ML, Pang YP, Lockridge O, Brimijoin S. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J. Pharmacol. Exp. Ther. 302, 710-716 (2002).
55. Gao Y, Brimijoin S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J. Pharmacol. Exp. Ther. 310, 1046-1052 (2004).
56. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62, 220-224 (2002).
57. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharmacol. 67, 204-211 (2005).
58. Pancook JD, Pecht G, Ader M, Mosko M, Lockridge O, Watkins JD. Application of directed evolution technology to optimize the cocaine hydrolase activity of human butyrylcholinesterase. FASEB J. 17, A565 (2003) (Abstract).
59. Gao Y. Brimijoin S. Viral transduction of cocaine hydrolase in brain reward centers. Cell. Mol. Neurobiol. 26, 357-363 (2006).
60. Pan Y, Gao D, Yang W et al. Computational redesign of human butyrylcholinesterase fbr anticocaine medication. Proc. Natl Acad. Sci. USA 102, 16656-16661 (2005).
61. Cooper ZD, Narasimhan D, Sunahara RK et al. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol. 70, 1885-1891 (2006).
62. Ko MC, Bowen LD, Narasimhan D et al. Cocaine esterase: interactions with cocaine and immune responses in mice. J. Pharmacol. Exp. Ther. 320, 926-933 (2007).
63. Woods J. Cocaine esterase: a novel enzyme therapy for cocaine abuse. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada, 20 June, 2007.
64. Hanson CV, Nishiyama Y, Paul S. Catalytic antibodies and their applications. Curr. Opin. Biotechnol. 16, 631-636 (2005).
65. McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD. Identification and characterization of single chain anti-cocaine catalytic antibodies. J. Mol. Biol. 365, 722-731 (2007).
66. Deng SX, de Prada P, Landry DW. Anticocaine catalytic antibodies. J. Immunol. Methods 269, 299-310 (2002).
67. Homayoun P, Mandal T, Landry D, Komiskey H. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. J. Pharm. Pharmacol. 55, 933-938 (2003).
68. Gatley SJ, MacGregor RR, Fowler JS, Wolf AP, Dewey SL, Schlyer DJ. Rapid stereoselective hydrolysis of (+)-cocaine in baboon plasma prevents its uptake in the brain: implications for behavioral studies. J. Neurochem. 54, 720-723 (1990).
69. Finkle BS, McCloskey KL. The forensic toxicology of cocaine (1971-1976). J. Forensic Sci. 23, 173-189 (1978).
70. Stephens BG, Jentzen JM, Karch S, Mash DC, Wetli CV. Criteria for the interpretation of cocaine levels in human biological samples and their relation to the cause of death. Am. J. Forensic Med. Pathol. 25, 1-10 (2004).
71. Lockridge O, Schopfer LM, Winger G, Woods JH. Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J. Med. Chem. Biol. Radiol. Def. 3, 5095 (2005).
72. Huang YJ, Huang Y, Baldassarre H et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl Acad. Sci. USA 104, 13603-13608 (2007).
73. Hall W, Carter L. Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. J. Med. Ethics 30, 337-340 (2004).
74. Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol. Rev. 23, 135-143 (2004).